CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease
2011

CX3CL1 Reduces Neurotoxicity in Parkinson's Disease Model

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): Mibel M Pabon, Adam D Bachstetter, Charles E Hudson, Carmelina Gemma, Paula C Bickford

Primary Institution: University of South Florida, College of Medicine

Hypothesis

Can exogenous CX3CL1 decrease microglia activation and minimize neurodegeneration in a rat model of Parkinson's disease?

Conclusion

CX3CL1 has a neuroprotective role in reducing microglia activation and neuronal loss in a model of Parkinson's disease.

Supporting Evidence

  • CX3CL1 treatment resulted in a significant reduction in lesion volume in the striatum.
  • All doses of CX3CL1 showed a similar protective effect on TH+ terminals.
  • Microglia activation was significantly reduced in CX3CL1 treated rats compared to controls.

Takeaway

This study found that a protein called CX3CL1 can help protect brain cells in rats with a disease similar to Parkinson's by calming down harmful brain cells.

Methodology

Rats were treated with different doses of CX3CL1 after a neurotoxic insult, and various brain regions were analyzed for neuronal loss and microglia activation using immunohistochemistry and stereological methods.

Potential Biases

Potential bias due to the lack of direct measurements of cytokine levels and the specific animal model used.

Limitations

The study did not measure direct cytokine levels to confirm the mechanism of CX3CL1's effects.

Participant Demographics

3-month-old male Fisher 344 rats.

Statistical Information

P-Value

0.0029

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1742-2094-8-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication